Does Pfizer Look Like a Buy? | equities.com - 0 views
-
Equities Group on 13 Sep 11Enthusiasm for the bitoech sector has been dwindling as investors avoid doubling up on volatility in the current market but Pfizer's latest rheumatoid arthritis may tempt the pro-risk buyer.